DURHAM, N.C., May 20, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that Doug Plessinger, Vice President of Clinical and Medical Affairs, is scheduled to present at the Sachs Cancer Bio Partnering Forum at the Westin Copley Place in Boston.
|Event:||The Sachs Cancer Bio Partnering Forum|
|Date:||Tuesday, May 21st, 2013|
|Time:||1:20 pm ET|
Mr. Plessinger will also participate in the "Immunotherapies & Cancer Vaccines" panel on May 21 at 4:00pm ET, which will focus on the evolving landscape of cancer immunotherapies today, as well as highlight the recent industry developments.
About the Arcelis™ Technology Platform
Arcelis is a fully personalized, active immunotherapy technology that captures all antigens, including mutated and variant antigens that are specific to each patient's disease. It has been shown to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that are associated with toxicity. The technology can be leveraged to manufacture personalized therapies for any cancer or infectious disease.
The Arcelis process integrates readily into many current treatment paradigms, using only a small tumor or blood sample and the patient's own dendritic cells, which are derived and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient sample to program the dendritic cells to target the entire disease-antigen repertoire. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered as an intradermal injection to produce the desired patient-specific immune response.
Arcelis technology also overcomes many of the manufacturing and commercialization challenges that have impeded other personalized cancer immunotherapies. Automated processes allow a single facility to serve all of North America and can be used to treat any cancer or infectious disease with the same manufacturing process and equipment.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate AGS-003 has initiated a Phase 3 study for the treatment of mRCC, and the Company plans to have data from its Phase 2b study of AGS-004 for the treatment of HIV in late 2013. For more information about Argos Therapeutics, visit www.argostherapeutics.com.
CONTACT: The Ruth Group Caitlin Cox (media) email@example.com (646) 536-7033 Stephanie Carrington (investors) firstname.lastname@example.org (646) 536-7017 Argos Therapeutics Jeff Abbey (partners) email@example.com (919) 287-6308Source: Argos Therapeutics